Abstract:Different biological subtype breast cancers respond differently to neoadjuvant chemotherapy, but it is unknown whether neoadjuvant or adjuvant chemotherapy leads to different long-term survival in each specific subtype although equal outcomes have been reported in general population. This study sought to clarify whether the selection of either neoadjuvant or adjuvant chemotherapy was linked to a differential survival benefit based on breast cancer subtypes. A prospectively maintained breast cancer database was queried from 2000 to 2008. All patients with a diagnosis of stage II and III breast cancer who received neoadjuvant or adjuvant chemotherapy were identified, only patients receiving docetaxel and epirubicin (TA) regimen were included. Patients were divided according to the administration of neoadjuvant or adjuvant chemotherapy. The biological subtypes were determined by immunohistochemical tests. The outcomes between neoadjuvant and adjuvant chemotherapy were compared in each different subtype. Kaplan-Meier curves were generated, and the Cox model was used to estimate the association between death risk and chemotherapy timing while adjusting for potentially confounding factors. P values < .05 were considered statistically significant. Of the 406 patients included, 201 (49.5%) received neoadjuvant chemotherapy, and 205 (50.5%) received an adjuvant TA regimen. Patients with the HER2+ and TNBC subtypes showed significantly higher pCR rates than patients with luminal types (P<.05). In general population, the neoadjuvant and adjuvant chemotherapy groups showed little survival variance (HR=1.15, 95% confidence interval (CI).691.91, P=.60). In luminal B-like patients, neoadjuvant chemotherapy led to worse overall survival (OS) than adjuvant therapy (HR=2.92, 95% CI 1.20 to 8.31, P=.02). In patients with the HER2+ subtype, neoadjuvant treatment corresponded to better OS(HR=.10, 95% CI.02-.58, P=.01). In contrast, patients with luminal A-like (HR=1.14, 95% CI.53-2.43, P=.74) and TNBC disease (HR=1.00, 95% CI.27-3.73, P=>.99) who underwent neoadjuvant chemotherapy showed equivalent OS when compared to patients undergoing adjuvant therapy. Neoadjuvant versus adjuvant chemotherapy results in a disparate impact on overall survival among patients with variant subtype breast cancer. When neoadjuvant chemotherapy was given, luminal B-like patients showed worse outcome, while patients with HER2+ disease had better OS. Prospective studies are necessary to determine and optimize the timing of chemotherapy for breast cancers with different molecular backgrounds.

Clinical Value of Molecular Subtypes for Breast Cancer Predicting Therapeutic Effect and Prognosis of Dose Dense Docetaxel Neoadjuvant Chemotherapy

247P KN026 in Combination with Docetaxel As Neoadjuvant Treatment for HER2+ Early or Locally Advanced Breast Cancer (BC): A Single-Arm, Multicenter, Phase II Study

Effects of Core Needle Biopsy and Subsequent Neoadjuvant Chemotherapy on Molecular Alterations and Outcome in Breast Cancer

A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer

Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?

Relationship Between Tumor Markers, ER/PR, HER2, Ki67 and CyclinA2 and Clinical Efficacy of Neoadjuvant Chemotherapy

Neoadjuvant Versus Adjuvant Chemotherapy with Taxanes and Anthracycline-Based Regimen: Which Leads to Better Outcome in Patients with Different Subtype Breast Cancer?

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial

Efficacy and Safety of Neoadjuvant Therapy for HER2-positive Early Breast Cancer: a Network Meta-Analysis

[Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients]

Assessment of neoadjuvant chemotherapy for breast cancer in 40 patients

Short-term Curative Effects of Docetaxel Combined with Capecitabine in Neoadjuvant Chemotherapy of Triple-negative Breast Cancer and Non Triple-negative Brest Cancer

Clinical significance of four subtypes of breast cancer

Efficacy and Safety of Docetaxel Combined with Oxaliplatin As A Neoadjuvant Chemotherapy Regimen for Chinese Triple-Negative Local Advanced Breast Cancer Patients A Prospective, Open, and Unicentric Phase Ii Clinical Trial

[Relationship Between Ki67 Expression and Tumor Response to Neoadjuvant Chemotherapy with Anthracyclines Plus Taxanes in Breast Cancer].

Clinical Efficacy of Neoadjuvant Chemotherapy Combined with Trastuzumab for HER-2 Positive Breast Cancer

Molecular Subtype Can Predict the Response and Outcome of Chinese Locally Advanced Breast Cancer Patients Treated with Preoperative Therapy

Clinicopathological characteristics and survival analysis of different molecular subtypes of breast invasive ductal carcinoma achieving pathological complete response through neoadjuvant chemotherapy

Analysis of Neoadjuvant Docetaxel, Carboplatin and Trastuzumab (TCH) in HER-2-positive Breast Cancer

Clinical Characteristics and Prognosis of Different Subtypes of Breast Cancer

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients